What is the significance of the FDA accepting the BLA for tislelizumab?

The acceptance of the Biologics License Application (BLA) by the FDA means that the agency has determined the submission is complete and will now conduct a full review of tislelizumab for the treatment of esophageal squamous cell carcinoma. This is a critical step towards potential market approval in the United States.

What does accelerated approval for BRUKINSA® mean?

Accelerated approval allows the FDA to approve drugs for serious conditions based on clinical trials that demonstrate a significant improvement in a surrogate endpoint or intermediate clinical outcome that is reasonably likely to predict clinical benefit. This often means the drug can reach patients faster, but it typically requires post-approval confirmatory trials to verify clinical benefit.

What is the target patient population for these approved/reviewed drugs?

Tislelizumab is being reviewed for patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic therapy. BRUKINSA® is approved for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.

When can investors expect a final decision on tislelizumab?

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of July 12, 2022, for the tislelizumab BLA. This is the date by which the FDA is expected to make a decision on the approval.

ONC/BEIGF 8-K SEC Disclosure

Summary

BeiGene, Ltd. (ONC) has filed an 8-K report detailing two significant regulatory milestones announced on September 13th and September 15th, 2021. The U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for tislelizumab, an anti-PD-1 antibody, as a treatment for a specific type of esophageal cancer. This acceptance sets a Prescription Drug User Fee Act (PDUFA) target action date of July 12, 2022, indicating a crucial step towards potential market approval. Furthermore, BeiGene announced that its drug BRUKINSA® (zanubrutinib) has received accelerated approval from the FDA. This approval is for adult patients suffering from relapsed or refractory marginal zone lymphoma (MZL) who have previously undergone at least one anti-CD20-based treatment regimen. These developments represent important advancements in BeiGene's drug pipeline and therapeutic offerings for cancer patients.

Key Highlights

1FDA accepted BLA for tislelizumab (anti-PD-1 antibody) for esophageal squamous cell carcinoma (ESCC).
2PDUFA target action date for tislelizumab BLA is July 12, 2022.
3BRUKINSA® (zanubrutinib) received accelerated approval from the FDA.
4BRUKINSA® approval is for adult patients with relapsed or refractory marginal zone lymphoma (MZL) after prior anti-CD20 therapy.
5These are two separate, significant regulatory events for BeiGene's drug candidates.
6The filing incorporates press releases detailing these announcements as exhibits.

BeOne Medicines Ltd. 8-K Report, Corporate Update (Sep 15, 2021)

Summary

Key Highlights

Frequently Asked Questions